Quality of Life Claims In Sanctura Journal Advertisement Cited By FDA
FDA sets a high bar for the type of data needed to substantiate a "quality of life" claim in a letter citing a journal advertisement for Indevus/ Allergan's overactive bladder treatment Sanctura
You may also be interested in...
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
WellPoint's updated formulary submission guidelines aim to give drug companies more detailed advice on submitting information on a drug's cost-effectiveness and its impact on pharmacy and medical budgets, as well as its effectiveness in improving patients' quality of life
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.